Lyrica (Pfizer) as effective as Keppra (UCB) for Epilepsy treatment
Top-line results are reported by Pfizer for a Phase III study that showed Lyrica (pregabalin) Capsules CV were as effective as Keppra (levetiracetam) from UCB, as an adjunctive therapy in adult Epilepsy patients experiencing refractory partial onset seizures. The top-line results indicate that the study met its primary endpoint by demonstrating that a comparable proportion of patients on Lyrica achieved at least a 50 percent reduction in the 28-day seizure rate during the maintenance phase relative to levetiracetam. The adverse event profile in the study was consistent with that known for Lyrica.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins